Abstract | PURPOSE: MATERIALS AND METHODS: We selected 25 patients with Peyronie's disease who did not have calcified plaque for treatment in the andrology outpatient clinic. A medical history was obtained, and physical examination, penile x-ray, penile ultrasound and pharmacologically induced erection with prostaglandin E1 were performed. Patients were randomly divided into group 1--those who received 20 mg. tamoxifen twice daily for 3 months and group 2--those who received placebo for the same period. The same evaluations were done 4 months later and results were compared. Qualitative (chi-square test) and quantitative (Student's t test) results were analyzed using the Yates correction factor with p <0.05 considered significant. RESULTS:
Pain subsided in 66.6 and 75% of the patients treated with tamoxifen and placebo, respectively (p >0.05). In groups 1 and 2 a reduction in the penile deformity was noticed by 46.1 and 41.7% of the patients (p >0.05), and a decrease in plaque size was noticed by 30.7 and 25%, respectively. On the other hand, objective measurements did not reveal any difference in plaque area or curvature angle. CONCLUSIONS: This study did not show significant improvement in pain, curvature or plaque size in patients with Peyronie's disease who were treated with tamoxifen compared with those treated with placebo.
|
Authors | C Teloken, E L Rhoden, T M Grazziotin, C T Ros, P R Sogari, C A Souto |
Journal | The Journal of urology
(J Urol)
Vol. 162
Issue 6
Pg. 2003-5
(Dec 1999)
ISSN: 0022-5347 [Print] United States |
PMID | 10569556
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Administration, Oral
- Aged
- Humans
- Male
- Middle Aged
- Penile Induration
(drug therapy)
- Tamoxifen
(administration & dosage)
|